Phase II Study of Oxaliplatin, Xeloda, and cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Apr 2018
At a glance
- Drugs Capecitabine (Primary) ; Cetuximab (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Mar 2018 Planned End Date changed from 28 Jun 2018 to 28 Jun 2019.
- 28 Mar 2018 Planned primary completion date changed from 28 Dec 2017 to 28 Dec 2018.